Werkgroep Cardiologische centra Nederland

EMPACT-MI (Recruiting)

a streamlined, multicentre, randomised, double-blind superiority study to evaluate efficacy and safety of empagliflozin 10 mg once daily compared to placebo, in patients hospitalised for acute myocardial infarction with high risk of heart failure and mortality
Medicine
Empagliflozin
Population
ASCVD
Phase
III
Starting year
2020

Director of Study

dr. Tj.J. Römer (Cardioloog)
Leiden, Alrijne Ziekenhuis